Kuo‐Yen Huang

1.7k total citations
43 papers, 1.3k citations indexed

About

Kuo‐Yen Huang is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kuo‐Yen Huang has authored 43 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kuo‐Yen Huang's work include Lung Cancer Treatments and Mutations (6 papers), Virus-based gene therapy research (5 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Kuo‐Yen Huang is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Virus-based gene therapy research (5 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Kuo‐Yen Huang collaborates with scholars based in Taiwan, Australia and United States. Kuo‐Yen Huang's co-authors include Pan‐Chyr Yang, Jau Tang, Ivan M. Kempson, Zi‐Xian Liao, Pyng Yu, Hsin‐Jung Li, Shuenn‐Chen Yang, S.‐Ja Tseng, Tong‐Hong Wang and Chi‐Yuan Chen and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and ACS Nano.

In The Last Decade

Kuo‐Yen Huang

43 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kuo‐Yen Huang Taiwan 21 520 320 208 180 176 43 1.3k
Haochen Yu China 18 468 0.9× 276 0.9× 168 0.8× 252 1.4× 187 1.1× 54 1.2k
Xi Xu China 22 503 1.0× 337 1.1× 159 0.8× 190 1.1× 301 1.7× 63 1.3k
Shuang Zhou China 18 377 0.7× 219 0.7× 224 1.1× 139 0.8× 80 0.5× 35 1.1k
Rong Shen China 23 586 1.1× 347 1.1× 282 1.4× 204 1.1× 92 0.5× 91 1.5k
Satoshi Sakamoto Japan 22 644 1.2× 210 0.7× 209 1.0× 69 0.4× 67 0.4× 77 1.5k
Zhimei Li China 23 1.1k 2.1× 299 0.9× 102 0.5× 441 2.5× 169 1.0× 74 1.9k
Yulian Wu China 19 410 0.8× 186 0.6× 120 0.6× 158 0.9× 79 0.4× 42 843
Zhiwei Sun China 24 1.2k 2.4× 305 1.0× 450 2.2× 416 2.3× 81 0.5× 54 1.8k
Lijuan Li China 16 409 0.8× 232 0.7× 100 0.5× 83 0.5× 100 0.6× 59 970

Countries citing papers authored by Kuo‐Yen Huang

Since Specialization
Citations

This map shows the geographic impact of Kuo‐Yen Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kuo‐Yen Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kuo‐Yen Huang more than expected).

Fields of papers citing papers by Kuo‐Yen Huang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kuo‐Yen Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kuo‐Yen Huang. The network helps show where Kuo‐Yen Huang may publish in the future.

Co-authorship network of co-authors of Kuo‐Yen Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Kuo‐Yen Huang. A scholar is included among the top collaborators of Kuo‐Yen Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kuo‐Yen Huang. Kuo‐Yen Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chao, Tai‐Ling, Yu‐Chi Chou, Yi Yao, et al.. (2025). The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation. Journal of Biomedical Science. 32(1). 59–59. 1 indexed citations
2.
Chen, Chi‐Yuan, Kuo‐Yen Huang, Chih‐Cheng Chen, et al.. (2024). The role of PM2.5 exposure in lung cancer: mechanisms, genetic factors, and clinical implications. EMBO Molecular Medicine. 17(1). 31–40. 18 indexed citations
3.
Wang, Tong‐Hong, Kuo‐Yen Huang, Chih‐Cheng Chen, et al.. (2023). PM2 .5 promotes lung cancer progression through activation of the AhR‐TMPRSS2‐IL18 pathway. EMBO Molecular Medicine. 15(6). e17014–e17014. 49 indexed citations
4.
Lin, Chia‐Yi, Kuo‐Yen Huang, Shih-Han Kao, et al.. (2023). Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response. Science Advances. 9(14). eade9944–eade9944. 25 indexed citations
5.
Hong, Xuan, Min‐Tsang Hsieh, Hui‐Yi Lin, et al.. (2023). Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma. Journal of Biological Chemistry. 299(6). 104814–104814. 6 indexed citations
6.
Wang, Tong‐Hong, Yann‐Lii Leu, Chih‐Cheng Chen, et al.. (2022). Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S. Phytotherapy Research. 36(5). 2116–2126. 3 indexed citations
7.
Huang, Kuo‐Yen, Tong‐Hong Wang, Chih‐Cheng Chen, et al.. (2021). Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin. Biomolecules. 11(9). 1271–1271. 39 indexed citations
8.
Chang, Sui‐Yuan, Kuo‐Yen Huang, Tai‐Ling Chao, et al.. (2021). Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses. Scientific Reports. 11(1). 8692–8692. 32 indexed citations
9.
Lin, Chia‐Yi, Kuo‐Yen Huang, Yi‐Chun Lin, et al.. (2021). Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer. Cancer Letters. 508. 76–91. 20 indexed citations
10.
Wang, Tong‐Hong, Chih‐Ching Wu, Kuo‐Yen Huang, et al.. (2020). Profiling of subcellular EGFR interactome reveals hnRNP A3 modulates nuclear EGFR localization. Oncogenesis. 9(4). 40–40. 16 indexed citations
11.
12.
Huang, Kuo‐Yen, Shuenn-Chen Yang, Sean M. Wu, et al.. (2020). Monocarboxylate Transporter 4 Is a Therapeutic Target in Non-small Cell Lung Cancer with Aerobic Glycolysis Preference. Molecular Therapy — Oncolytics. 18. 189–201. 27 indexed citations
13.
Chen, Zhong, Kuo‐Yen Huang, Yong Ling, et al.. (2019). Discovery of an Oleanolic Acid/Hederagenin–Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer. Journal of Natural Products. 82(11). 3065–3073. 41 indexed citations
14.
Wu, Yi-Ying, Kuo‐Yen Huang, Shuenn-Chen Yang, et al.. (2019). The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. Journal of Experimental & Clinical Cancer Research. 38(1). 282–282. 37 indexed citations
15.
Liao, Zi‐Xian, et al.. (2017). Light-triggered methylcellulose gold nanoparticle hydrogels for leptin release to inhibit fat stores in adipocytes. International Journal of Nanomedicine. Volume 12. 7603–7611. 15 indexed citations
16.
Huang, Kuo‐Yen, et al.. (2016). Synthesis of Ni(OH)2 nanoflakes on ZnO nanowires by pulse electrodeposition for high-performance supercapacitors. Journal of Power Sources. 308. 29–36. 74 indexed citations
17.
Huang, Kuo‐Yen, Shih-Han Kao, Chi‐Yuan Chen, et al.. (2015). Small Molecule T315 Promotes Casitas B-Lineage Lymphoma–Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation. American Journal of Respiratory and Critical Care Medicine. 193(7). 753–766. 18 indexed citations
18.
19.
Yuan, Chi‐Tsu, Yonggang Wang, Kuo‐Yen Huang, et al.. (2011). Single-Particle Studies of Band Alignment Effects on Electron Transfer Dynamics from Semiconductor Hetero-nanostructures to Single-Walled Carbon Nanotubes. ACS Nano. 6(1). 176–182. 22 indexed citations
20.
Hung, Li‐Feng, Kuo‐Yen Huang, Deng‐Ho Yang, et al.. (2010). Advanced glycation end products induce T cell apoptosis: Involvement of oxidative stress, caspase and the mitochondrial pathway. Mechanisms of Ageing and Development. 131(11-12). 682–691. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haochen Yu Breakdown of academic impact, for papers by Xi Xu Breakdown of academic impact, for papers by Shuang Zhou Breakdown of academic impact, for papers by Rong Shen Breakdown of academic impact, for papers by Satoshi Sakamoto Breakdown of academic impact, for papers by Zhimei Li Breakdown of academic impact, for papers by Yulian Wu Breakdown of academic impact, for papers by Zhiwei Sun Breakdown of academic impact, for papers by Lijuan Li
Rankless by CCL
2026